Description
Product Properties
|
Property Name |
Property Details |
|
Alternative Names |
FGF-8, FGF 8, FGF-8a, FGF8a |
|
Species |
Human |
|
Expression Region |
Gln23–Arg204 |
|
Accession |
P55075-2 |
|
Tag |
No Tag |
|
Expression System |
E. coli |
|
Molecular Weight |
The protein has a predicted MW of 21.20 kDa, same as SDS-PAGE result. |
|
Purity |
> 95% as determined by SDS-PAGE. |
|
Endotoxin |
< 1.0 EU per μg by the LAL method. |
|
Formulation |
Lyophilized from 0.22 μm filtered solution in 20 mM Tris-HCl, 300 mM NaCl (pH 8.5). Normally 8% mannitol is added as protectant before lyophilization. |
|
Appearance |
Lyophilized Powder |
|
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water. |
Features
High purity, high bioactivity, low endotoxin, excellent lot-to-lot consistency
Storage
Store at -25°C to -15°C, valid for 1 year upon receipt.
After reconstitution, store at -85°C to -65°C, valid for 3 months.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.